Hans‐Willi Krell

Statistics

Publications

Citations

1.9K

H-Index

Active since

1984

Affiliations

Roche Pharma AG (Germany)(Current)

Roche (Switzerland)

University of Liège

Charité - Universitätsmedizin Berlin

University of Freiburg

Hans‐Willi Krell is an author at Roche Pharma AG (Germany) specializing in matrix metalloproteinases, matrix metalloproteinase inhibitors, and life sciences.

Publications per year

1984–2011

Publications

Interleukin (IL)-23 mediates <i>Toxoplasma gondii</i>–induced immunopathology in the gut via matrixmetalloproteinase-2 and IL-22 but independent of IL-17

Melba Muñoz, Markus M. Heimesaat, Kerstin Danker et al. · The Journal of Experimental Medicine · 2009 · 276 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

MMP‐2 and MMP‐9 synergize in promoting choroidal neovascularization

Vincent Lambert, Ben Wielockx, Carine Munaut et al. · The FASEB Journal · 2003 · 188 citations · Full text

Medicine, Molecular Medicine, Ophthalmology +17

Human meprin alpha and beta homo-oligomers: cleavage of basement membrane proteins and sensitivity to metalloprotease inhibitors

Markus-N. Kruse, Christoph Becker, Daniel Lottaz et al. · Biochemical Journal · 2004 · 179 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +16

Anti-Invasive, Antitumoral, and Antiangiogenic Efficacy of a Pyrimidine-2,4,6-trione Derivative, an Orally Active and Selective Matrix Metalloproteinases Inhibitor

Erik Maquoi, Nor Eddine Sounni, Laetitia Devy et al. · Clinical Cancer Research · 2004 · 155 citations · Full text

Medicine, Oncology, Pharmacology +12

Tissue Inhibitor of Metalloproteinases-1 Promotes Liver Metastasis by Induction of Hepatocyte Growth Factor Signaling

Charlotte Kopitz, Michael Gerg, Obul Reddy Bandapalli et al. · Cancer Research · 2007 · 143 citations

Medicine, Cell Biology, Oncology +17

1–5 of 21